Disitamab Vedotin

This innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive.

RemeGen hopes for pain relief from expanded drug uses

The innovative drug company has so far brought only two products to market, and its high sales expenses make investors worry about fallout from an anti-corruption drive Key Takeaways: RemeGen’s…
9995.HK 688331.SHG

Recent Articles

RELATED ARTICLES

  1. RemeGen as problems and losses pile up
    No respite for RemeGen as problems and losses pile up
    9995.HK 688331.SHG
  2. Cancer drug maker Genfleet joins Hong Kong IPO influx
  3. Earnings blow for CSPC Pharma as the state drives a hard bargain
    1093.HK
  4. Xuanzhu Biopharm set for spin-off in Hong Kong IPO
    0460.HK
  5. Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
    1952.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva